Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives

被引:2
|
作者
Pack, Allison [1 ,2 ,7 ]
Russell, Andrea [1 ,2 ]
Kircher, Sheetal [1 ,2 ]
Weldon, Christine [1 ,2 ,3 ,4 ]
Bailey, Stacy C. [1 ,2 ]
Lockwood, Karen [5 ]
Marquart, Tyler [5 ]
Afonso, Ana Sofia [6 ]
Payakachat, Nalin [5 ]
Wolf, Michael [1 ,2 ]
机构
[1] Northwestern Univ, Ctr Appl Hlth Res Aging, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Univ, Div Obstet & Gynecol, Feinberg Sch Med, Chicago, IL USA
[4] Ctr Business Models Healthcare, Glencoe, IL USA
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Eli Lilly BV, Utrecht, Netherlands
[7] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, 750 N Lake Shore Dr, 10th Floor, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Non -small cell lung cancer; Patient education; Biomarker testing; LITERACY;
D O I
10.1016/j.pec.2023.107839
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: We qualitatively explored patient and clinician experiences with biomarker testing in one academic health system to identify current communication practices and unmet testing information needs. Methods: We conducted 1:1 in-depth interviews with 15 clinicians (i.e., nurses, oncologists, pathologists) and 12 patients diagnosed with non-small cell lung cancer between January and May 2022. Participants described experiences with biomarker testing as well as associated communication practices and needs. Interviews were audio-recorded and transcribed. Analysis was informed by the Framework Method. Results: Patients described challenges retaining information early in their patient journey. While patients were generally aware of biomarkers and their effect on treatment options, they expressed limited knowledge of expected time delays between testing and receiving results. Additionally, many did not know their testing results. Clinicians and patients both noted no standard education material on biomarker testing is currently available. They suggested such materials could support patient knowledge and decision-making. Conclusions: Communication between patients and clinicians about biomarker testing is largely delivered through verbal counseling at a time when patients may be cognitively compromised. All participants supported the idea of delivering standard, tangible education materials on biomarker testing to patients. Practice implications: Education materials may enhance counseling efforts and patient knowledge.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective
    Malapelle, Umberto
    Tiseo, Marcello
    Vivancos, Ana
    Kapp, Joshua
    Jose Serrano, M.
    Tiemann, Markus
    JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (03): : 255 - 273
  • [32] Access to biomarker testing in patients with advanced non-small cell lung cancer.
    Borghaei, Hossein
    Hirsch, Fred R.
    Wynes, Murry
    Ravelo, Arliene
    Ramalingam, Suresh S.
    Ionescu-Ittu, Raluca
    Pivneva, Irina
    Ganti, Apar Kishor
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer
    Fox, Adam H.
    Alexander, Mariam
    Forcucci, Jessica A.
    Silvestri, Gerard A.
    CHEST, 2024, 166 (05) : 1239 - 1249
  • [34] Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations
    Penault-Llorca, Frederique
    Socinski, Mark A.
    ONCOLOGIST, 2025, 30 (03):
  • [35] Patient and clinician perspectives on adjuvant treatment in early-stage non-small cell lung cancer (NSCLC): Qualitative results
    Collacott, H.
    Okhuoya, P.
    Sandelin, M.
    Michaels-Igbokwe, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S100 - S100
  • [36] Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
    Karunanithi, Vijayalakshmi
    Win, Thida
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [37] Molecular testing in non-small cell lung cancer
    Mahmood, Bayan
    Yin, Su Lei
    Muhammad, SyedAun
    Dancey, Gairin
    Medeiros, Filomena
    LUNG CANCER, 2022, 165 : S35 - S35
  • [38] Collagen XXIII: A biomarker for non-small cell lung cancer
    Spivey, Kristin A.
    Banyard, Jacqueline
    Solis, Luisa M.
    Wistuba, Ignacio I.
    Barletta, Justine A.
    Gandhi, Leena
    Feldman, Henry A.
    Rodig, Scott J.
    Chirieac, Lucian R.
    Zetter, Bruce R.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [39] BIOMARKER FOR BRAIN METASTASIS OF NON-SMALL CELL LUNG CANCER
    Yang, Seung-Ho
    Yoo, Jin Young
    Cho, Deog Gon
    Kim, Hoo Kyo
    Kim, Sung Whan
    Lee, Sang Won
    NEURO-ONCOLOGY, 2010, 12 : 64 - 64
  • [40] Osteopontin is a prognostic biomarker in non-small cell lung cancer
    Rud, Ane Kongsgaard
    Boye, Kjetil
    Oijordsbakken, Miriam
    Lund-Iversen, Marius
    Halvorsen, Ann Rita
    Solberg, Steinar K.
    Berge, Gisle
    Helland, Aslaug
    Brustugun, Odd Terje
    Maelandsmo, Gunhild M.
    BMC CANCER, 2013, 13